Cellectar Biosciences (CLRB) PT Raised to $5.50 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Kevin DeGeeter raised the price target on Cellectar Biosciences (NASDAQ: CLRB) to $5.50 (from $5.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
